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OBJECTIVES This study was designed to determine the association between race and atrial fibrillation (AF)
among patients with heart failure (HF).
BACKGROUND Atrial fibrillation is known to complicate HF, but whether its prevalence varies by race, and
the reasons why, are not well understood.
METHODS We identified adults hospitalized with confirmed HF within a large integrated healthcare
delivery system. We obtained information on demographics, comorbidity, vital signs,
medications, and left ventricular systolic function status. “Atrial fibrillation” was defined as
AF or atrial flutter documented by electrocardiogram or prior physician-assigned diagnoses.
We evaluated the independent relationship between race and AF using multivariable logistic
regression.
RESULTS Among 1,373 HF patients (223 African Americans, 1,150 Caucasians), the prevalence of AF
was 36.9% (95% confidence interval [CI] 34.3% to 39.5%). Compared with Caucasians,
African Americans were younger (mean age 67 vs. 74 years, p  0.001) and more likely to
have hypertension (86.6% vs. 77.7%, p  0.01) and prior diagnosed HF (79.4% vs. 70.7%, p
 0.01). African Americans had less prior diagnosed coronary disease, revascularization,
hypothyroidism, or valve replacement. Atrial fibrillation was much less prevalent in African
Americans (19.7%) than Caucasians (38.3%, p  0.001). After adjustment for risk factors for
AF and other potential confounders, African Americans had 49% lower odds of AF (adjusted
odds ratio 0.51, 95% CI 0.35 to 0.76).
CONCLUSIONS In a contemporary HF cohort, AF was significantly less common among African Americans
than among Caucasians. This variation was not explained by differences in traditional risk
factors for AF, HF etiology and severity, and treatment. (J Am Coll Cardiol 2004;43:
429–35) © 2004 by the American College of Cardiology Foundation
More than five million Americans currently have chronic
heart failure (HF), which remains the leading cause of
hospitalization in patients 65 years and older (1,2). Because
the incidence of HF markedly increases with advancing age,
and in light of the aging U.S. population, the number of
older patients with HF will increase substantially in the
coming decades.
See page 436
The risk of developing AF during long-term follow-up
appears to be 5 to 10 times higher in patients with chronic
HF than in persons without known HF (3–6). Approxi-
mately 15% to 30% of patients with HF will develop this
arrhythmia at some time during their clinical course (3,7–9).
Some studies have shown that the onset of AF in patients
with HF is associated with clinical and hemodynamic
deterioration due to loss of atrial contractility, tachycardia,
and lack of atrioventricular synchrony, as well as a poorer
long-term prognosis (10–12). Although the association
between HF and AF is well documented, risk factors for
developing AF in this setting are not well understood.
It has been postulated that among patients with HF,
African Americans may have a lower prevalence of AF than
Caucasians (13,14), as has been seen in the general adult
population without HF (15–17). However, African Amer-
icans with HF have a higher morbidity and mortality rate
than Caucasians with HF (10–12). Because AF is associ-
ated with higher morbidity and mortality rates in HF, it is
unclear whether the racial difference in prevalence of AF
may be diminished in the setting of HF. Previous studies
comparing the prevalence of AF in African Americans with
the prevalence of AF in Caucasians having HF have
provided only crude estimates that were not adjusted for
possible explanatory factors such as differences in HF
etiology, left ventricular (LV) systolic function, comorbid
illnesses, and variation in therapies received.
On the basis of existing published data, the prevalence of
AF has not been clearly defined in different racial groups,
along with potential factors that may explain any observed
racial differences in HF. Establishing race as an independent
risk factor may potentially help to better risk-stratify pa-
tients with HF. In addition, learning about different fre-
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quencies of complications of HF such as AF in various racial
groups may help guide clinicians in the monitoring, evalu-
ation, and management of these patients. Furthermore,
learning more about which types of patients with HF
develop AF may also yield important insights into the
pathogenesis of AF in this condition.
To address these issues, we examined the association
between race and prevalent AF in patients with HF receiv-
ing care within a large integrated healthcare delivery system.
METHODS
Study participants. The EPOCH (Epidemiology, Prac-
tice, Outcomes, and Cost of Heart Failure) Study is a cohort
study with retrospective and prospective components. This
cohort was assembled by taking a random sample of 1,700
from a total of 4,927 health plan members hospitalized with
a primary discharge diagnosis of HF between July 1, 1999,
and June 30, 2000, at any one of 16 Kaiser Permanente of
Northern California hospitals. A HF hospitalization was
defined as a primary discharge diagnosis of HF based on
relevant ICD-9-CM codes (402.01, 402.11, 402.91, 425.0,
425.1, 425.2, 425.3, 425.4, 425.7, 425.8, 425.9, 428.0,
428.1, or 428.9) found in hospitalization databases.
The presence of clinical HF was confirmed using the
Framingham Heart Study criteria for HF based on infor-
mation from inpatient medical records for the index hospi-
talization (18). For the purpose of our analyses, we excluded
327 patients who were neither Caucasian nor African
American based on our a priori hypothesis. Hispanic/Latino
patients were not considered Caucasian.
We performed a cross-sectional analysis using data from
1,150 Caucasian and 223 African American patients en-
rolled in the EPOCH study.
Definition of prevalent AF. “Prevalent AF” was defined as
the presence of AF or atrial flutter on electrocardiogram
(ECG) during the index hospitalization and/or as indicated
by a diagnosis found in medical records, hospitalization
databases, or ambulatory visit databases. “Electrocardio-
graphic AF” was defined as the presence of an irregularly
irregular rhythm with fibrillatory waves and no defined
P-waves (19). “Electrocardiographic atrial flutter” was de-
fined as the presence of typical or atypical flutter waves with
an atrial rate ranging from 250 to 350 per minute (19).
Diagnoses were based on physician-assigned diagnoses in
the medical records and/or the presence of corresponding
ICD-9-CM codes for AF (427.31) or atrial flutter (427.32)
in hospital discharge or ambulatory visit clinical databases
during the five years before the index hospitalization. We
have previously demonstrated the utility of using these
clinical databases for identifying diagnosed AF (15). We
also used the same time frame for ascertainment of a history
of AF for both African American and Caucasian subjects
from clinical databases and medical records.
Patient characteristics. Data collected on demographic
characteristics, co-morbid conditions, vital signs at presen-
tation, and medications were obtained from medical
records, supplemented by information from automated hos-
pitalization, ambulatory visit, pharmacy, and laboratory
health plan databases during the five years before the index
hospitalization. Demographic information included age,
gender, and self-reported race from automated databases.
For patients without self-reported race information, we
obtained race data from admission medical records. Infor-
mation about health-related behaviors, including past and
current use of tobacco, alcohol, heroin, amphetamine, or
cocaine, was based on medical records. Medical history
obtained from medical records as well as inpatient and
outpatient clinical databases included diagnosed hyperten-
sion, prior angina or coronary disease, prior known HF,
known cardiomyopathy or LV systolic dysfunction, valvular
disease (mitral and/or aortic stenosis or insufficiency) or
valve repair, diabetes mellitus, chronic lung disease, hyper-
thyroidism, hypothyroidism, prior ischemic stroke or tran-
sient ischemic attack, known peripheral arterial disease, and
prior coronary revascularization (i.e., percutaneous coronary
intervention or coronary artery bypass surgery).
Information on medications at presentation included the
use of aspirin, beta-adrenergic antagonists, calcium channel
antagonists, angiotensin-converting enzyme inhibitors, an-
giotensin II receptor blockers (ARBs), diuretics, or spirono-
lactone based on medical records and filled prescriptions
from the comprehensive outpatient pharmacy database dur-
ing the 120 days before admission. Physical exam findings at
presentation, including the presence or absence of tachycar-
dia (120 beats/min), inspiratory rales on pulmonary exam,
and an S3 gallop rhythm, were obtained by chart review.
Dictated reports of chest X-rays performed at presentation
for the index hospitalization were reviewed for diagnoses of
cardiomegaly, pleural effusions, and interstitial/alveolar
edema.
Duration of health plan membership and utilization of
outpatient services during the five years before the index
hospitalization were obtained from administrative files.
Presumed etiology of HF. “Ischemic HF” was defined as
being present when a patient had a documented history
of coronary heart disease, which included myocardial in-
farction, angina, coronary artery disease, or coronary re-
vascularization. All other cases of HF were considered
“nonischemic.”
LV systolic function status. To assign systematically LV
systolic function status, we used information on the quan-
titative estimate of LV ejection fraction (LVEF), with a
Abbreviations and Acronyms
AF  atrial fibrillation
ARB  angiotensin II receptor blocker
ECG  electrocardiogram/electrocardiographic/
electrocardiography
HF  heart failure
LV  left ventricle/ventricular
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preference for radionuclide scintigraphy over echocardiography
(transthoracic or transesophageal) followed by left ventriculo-
grams performed during cardiac catheterization. This was
based on the expected accuracy of these tests for quantitatively
measuring LVEF. Whenever possible, we used the intrahos-
pitalization or most recent post-hospitalization LVEF assess-
ment rather than pre-index hospitalization results, as this more
likely reflected the clinical status associated with the index
hospitalization. If quantitative measurements were not avail-
able, we used qualitative descriptions of LV systolic function
that were grouped into categories of severity (normal, mildly
reduced, moderately reduced, or severely reduced). In this case,
reduced systolic function was defined as LVEF 40% or a
qualitative description of moderately or severely reduced sys-
tolic function.
Statistical analysis. We examined baseline differences by
race (African Americans vs. Caucasians) and by AF status
using the Student t test for continuous variables and
chi-square test for categorical variables. The Fisher exact
test was used for categorical variables when the assumptions
of the chi-square test were not met (5 or fewer observations
in any cell). Using this criterion, the Fisher exact test was
used in the univariate analyses by race for cocaine use,
amphetamine use, heroin use, and history of mitral stenosis.
We used staged multivariable logistic regression models
to assess the independent relationship between race and
prevalent AF after sequentially controlling for different
categories of potential confounders. Variables available for
these models included race, age, gender, known risk factors
for AF (such as hypertension, coronary disease, prior diag-
nosed HF, diagnosed cardiomyopathy, hyperthyroidism,
mitral stenosis, chronic lung disease, and valvular repair),
LV function status, medications at presentation, other
comorbid conditions, physical examination findings, and
chest X-ray findings. In the first multivariate model, we
adjusted for only age and gender. In the next model, we
added known risk factors for AF. For the final model, we
added additional comorbid conditions, medications at pre-
sentation, LV systolic function status, physical examination
findings, and chest X-ray findings. Of note, digoxin use was
not included in the multivariable models given its high
correlation with the presence of AF. In addition, we
performed stratified analyses by HF etiology (ischemic vs.
nonischemic), gender (men vs. women), and age (60 vs.
60 years) and found no statistically significant interactions
between these variables and race; therefore, results from the
final multivariable model are presented. In the final multi-
variate model, we evaluated the goodness of fit using the
Hosmer-Lemeshow test. Finally, to address whether the
occurrence of transient HF due to primarily diastolic dys-
function and AF may explain any racial difference in
prevalent AF, we excluded patients who presented with
tachycardia and who were identified with AF by admission
ECG alone and repeated the final multivariable model. All
analyses were performed using SAS version 8.0 statistical
software (SAS Institute, Cary, North Carolina).
This study was approved by the Kaiser Foundation
Research Institute’s institutional review board.
RESULTS
Baseline characteristics and prevalence of AF. Among
1,373 patients hospitalized for HF, there were 223 African
American and 1,150 Caucasian subjects, with mean age of
73 years and 48% being women (Table 1). Seventy-two
percent of all subjects had a history of diagnosed HF, and
31% had known cardiomyopathy. Nearly 80% of patients
had a history of diagnosed hypertension. A history of
coronary disease was also common (65%), with approxi-
mately one-third of patients having had a prior myocardial
infarction and 27% having had a prior coronary revascular-
ization. Diagnosed valvular heart disease was relatively
uncommon, with the most prevalent diagnoses being mitral
regurgitation (9%) and aortic stenosis (7%). Among our
cohort, 46% had chronic lung disease. Approximately 90%
of patients were also taking a diuretic on hospital admission,
with more than 65% taking an angiotensin-converting
enzyme inhibitor and/or an ARB. More than 85% of
patients with confirmed HF had inspiratory rales on lung
examination, with 56% having interstitial edema on admis-
sion chest X-ray. Cardiomegaly on chest radiography was
present in the majority (80%) of patients, and 49% of
patients had evidence of pleural effusion. Heart failure with
preserved LV systolic function (defined as LVEF 40% or
qualitative assessment of normal or mildly reduced systolic
function) was present in 48% of subjects.
A total of 506 persons had evidence of AF, for an overall
prevalence in the cohort of 36.9% (95% CI 34.3% to 39.5%).
Among the patients with evidence of AF, 241 (47.6%) were
identified by ECG plus prior diagnoses found in medical
records or clinical databases, 170 (33.6%) by prior diagnoses
alone, and 95 (18.8%) by ECG alone during the index
hospitalization.
Race and AF. Compared with Caucasians, African Amer-
icans were younger but equally likely to be women (Table 1).
Hypertension, prior diagnosed HF, prior cardiomyopathy,
and radiographic cardiomegaly were more common in
African Americans than Caucasians. African Americans
were less likely to have a history of angina, hypothyroidism,
coronary revascularization, or valvular repair/replacement.
There were no significant racial differences in current or
former tobacco or alcohol use. Overall, illicit drug use was
low in both groups, with slightly higher current or former
cocaine and heroin use among African Americans. African
Americans were less likely than Caucasians to be taking a
beta-adrenergic antagonist on admission, but there were no
significant differences in the use of angiotensin-converting
enzyme inhibitors, ARBs, spironolactone, diuretics, aspirin,
or calcium channel antagonists. There were no significant
racial differences in selected measures of HF severity at
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presentation, including the presence of tachycardia, an S3
gallop rhythm, or interstitial edema on admission chest
X-ray. In addition, there were also no significant racial
differences in the distribution of LV systolic function status
(LVEF 40%, 40%, or unknown). Of note, duration of
membership during the five years before the index admis-
sion was similar between African American and Caucasian
patients (mean  SD: 4.4  1.3 vs. 4.5  1.3 years,
respectively), and outpatient utilization was not significantly
different during the 12 months before hospitalization in
both groups (data not shown).
African Americans had a 50% lower prevalence of AF
Table 1. Baseline Characteristics of 1,373 Patients Hospitalized With Heart Failure Between
July 1, 1999, and June 30, 2000, Stratified by Race
African Americans
(n  223)
Caucasians
(n  1,150) p Value
Demographic characteristics
Mean age  SD, yrs 67  14 74  12  0.001
Women, % 52% 47% 0.20
Medical history, %
Hypertension 87% 78%  0.01
Angina 17% 24% 0.01
Myocardial infarction 26% 32% 0.07
Coronary revascularization 13% 30%  0.001
PCI without stent 6% 12% 0.02
PCI with stent 1% 5% 0.01
Coronary artery bypass surgery 10% 25%  0.001
Valve repair or replacement 2% 7% 0.01
Known coronary disease 65% 65% 0.92
Prior heart failure 79% 71%  0.01
Cardiomyopathy 37% 29% 0.02
Diagnosed aortic stenosis 4% 7% 0.17
Diagnosed aortic insufficiency 4% 4% 0.97
Diagnosed mitral stenosis 0% 1% 0.38*
Diagnosed mitral insufficiency 8% 9% 0.47
Diabetes mellitus 48% 41% 0.07
Chronic lung disease 44% 46% 0.59
Hyperthyroidism 4% 3% 0.88
Hypothyroidism 10% 20% 0.001
Prior ischemic stroke/transient ischemic attack 25% 24% 0.70
Known peripheral arterial disease 19% 23% 0.17
Health-related behaviors, %
Current or former tobacco use 65% 61% 0.20
Current or former alcohol use 39% 40% 0.63
Current or former cocaine use 2% 0%  0.01*
Current or former amphetamine use 1% 1% 0.62*
Current or former heroin use 2% 0%  0.01*
Medications on admission, %
Aspirin 47% 49% 0.54
Beta-adrenergic antagonist 31% 38% 0.05
Calcium channel antagonist 34% 31% 0.40
Angiotensin-converting enzyme inhibitor 65% 64% 0.71
Angiotensin receptor blocker 10% 9% 0.49
Diuretic 87% 91% 0.11
Spironolactone 15% 12% 0.28
Physical examination findings at presentation, %
Tachycardia (120 beats/min) 12% 15% 0.20
Inspiratory rales 83% 86% 0.30
S3 gallop rhythm 13% 11% 0.20
Chest radiographic findings, %
Cardiomegaly 89% 78% 0.001
Pleural effusion 35% 51%  0.001
Interstitial/alveolar edema 54% 56% 0.58
Left ventricular ejection fraction status, % 0.11
40% 51% 47%
40% 40% 39%
Unknown 9% 14%
*Based on Fisher exact test.
PCI  percutaneous coronary intervention.
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(19.7%, 95% CI 14.7% to 25.6%) than Caucasians (38.3%,
95% CI 35.4% to 41.1%, p  0.001) (Fig. 1). There was no
significant difference in the prevalence of atrial flutter
between African Americans and Caucasians (4.5% vs. 6.5%,
respectively, p 0.25). After adjusting for differences in age
and gender, African American race was associated with 45%
decreased odds (95% CI 22% to 61%) of prevalent AF
(Table 2). In the final model that adjusted for differences in
age, gender, known risk factors for AF (hypertension,
coronary disease, prior diagnosed HF, mitral stenosis, val-
vular repair, chronic lung disease, and hyperthyroidism),
differences in HF therapy before admission, LV systolic
function status (LVEF 40%, 40%, or unknown), and
other co-morbid conditions, African Americans still had
49% (95% CI 24% to 65%) decreased odds of having AF
compared with Caucasians (Table 2). In the final model,
age, prior HF, prior known mitral insufficiency, prior known
valvular disease, diabetes, selected medications at admission
(aspirin, calcium channel blockers, and diuretics), LV sys-
tolic function status, tachycardia at presentation, presence of
S3 on physical exam, and cardiomegaly on admission chest
X-ray were also significant correlates of AF. The final
multivariable model had acceptable goodness of fit (p 
0.70 by Hosmer-Lemeshow test). To address whether racial
differences in prevalent AF may be explained by the differ-
ential occurrence of transient HF due to rapid AF and
diastolic dysfunction, we excluded the 34 patients who
presented with tachycardia and whose AF was identified
only by the admission ECG, but we found that the results
were similar (adjusted odds ratio 0.54, 95% CI 0.36 to 0.79).
Figure 1. Prevalence of atrial fibrillation between African American and Caucasian patients hospitalized with heart failure.
Table 2. Multivariable Analyses of the Association Between Race and Prevalent Atrial
Fibrillation Among Hospitalized Patients With Heart Failure
Prevalent Atrial Fibrillation
African Americans vs. Caucasians
Odds Ratio (95% Confidence Interval) p Value
Unadjusted 0.44 (0.31–0.62)  0.001
Adjusted for age and gender 0.55 (0.39–0.78)* 0.001
Adjusted for age, gender, known risk factors
for atrial fibrillation†
0.54 (0.38–0.77)‡ 0.001
Adjusted for age, gender, known risk factors
for atrial fibrillation†, other co-morbid
conditions§, medications at presentation,
and left ventricular systolic function
status¶
0.51 (0.35–0.76)#  0.001
*Age was also a significant predictor. †Known risk factors for atrial fibrillation include hypertension, coronary disease, prior
diagnosed heart failure, diagnosed cardiomyopathy, hyperthyroidism, mitral stenosis, chronic lung disease, and valvular repair.
‡Age, history of heart failure, and prior known valvular disease were also significant predictors. §Comorbid conditions include
angina, myocardial infarction, aortic stenosis, aortic insufficiency, mitral insufficiency, peripheral vascular disease, hypothyroid-
ism, diabetes mellitus, coronary bypass, percutaneous coronary intervention, PCI with or without stent, and tobacco use.
Medications at presentation included beta-adrenergic antagonist, calcium channel antagonist, aspirin, spironolactone, and
diuretics. ¶Included left ventricular ejection fraction of 40%, 40%, or unknown. #Age, history of heart failure, prior known
mitral insufficiency, prior known valvular disease, diabetes, selected medications at admission (aspirin, calcium channel blockers,
and diuretics), left ventricular systolic function, tachycardia at presentation, presence of S3 on physical exam, and presence of
cardiomegaly on admission chest X-ray were also significant predictors.
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DISCUSSION
Atrial fibrillation is highly prevalent among patients with
HF and can lead to adverse consequences, including
tachycardia-related cardiomyopathy, reduction in LV pre-
load attributable to disorganized atrial contractions, in-
creased risk of systemic embolus, and overall poorer long-
term outcome (10–12). However, whether AF occurs at the
same frequency among different race/ethnic groups has not
been well understood. In a large cohort of patients hospi-
talized with confirmed HF, we found that AF affected more
than one-third of patients. Furthermore, we observed that
the prevalence of AF was nearly 50% less among African
American than Caucasian patients and that this difference
only minimally decreased after adjustment for known risk
factors for AF, relevant patient characteristics, severity of
HF presentation, LV systolic dysfunction status, presumed
HF etiology, and medical management before hospital
admission.
Our finding of a prevalence of AF of 36.9% in HF
patients was slightly higher than the National Heart Failure
Project sample of Medicare beneficiaries hospitalized for
HF (29.5%) (20), although the exact definition of AF used
in the National Heart Failure Project was not clear. How-
ever, our prevalence estimate was similar to that reported by
Aronow et al. (35.2%) in a smaller sample of elderly,
long-term nursing home residents diagnosed with HF (11).
These relatively minor differences are likely explained by
differences in populations and methods used to ascertain
AF.
We observed that AF is approximately 50% less prevalent
in African Americans than Caucasians with HF, which is
consistent with estimates from prior studies (13,14). In a
cohort study of 398 patients age 50 years or older hospital-
ized with HF, Vaccarino et al. (14) reported a prevalence of
AF of 28.0% in Caucasians and 14.6% in African Ameri-
cans. Among 163 consecutive patients admitted for HF at
an urban hospital, Afzal et al. (13) reported a prevalence of
AF of 42% in Caucasians and 21% in African Americans.
However, these studies included relatively modest numbers
of subjects, and more importantly, did not adjust for
potential confounders to examine the independent relation-
ship between race and AF. In our study, African Americans
generally had a more adverse risk profile for AF (3),
including a higher frequency of diagnosed hypertension,
prior diagnosed HF or cardiomyopathy, and diabetes, al-
though they were also younger and had a lower prevalence
of diagnosed hypothyroidism. The lower prevalence of AF
in African Americans with HF in this cohort persisted even
after adjustment for these known risk factors for AF, as well
as presumed HF etiology (ischemic vs. nonischemic), dif-
ferences in cardiac medication use at presentation, other
relevant co-morbid illnesses, selected measures of HF se-
verity, and LV systolic function status.
The reason for the difference in prevalence of AF by race
remains unclear. One possibility is that the difference could
be a result of unmeasured confounders such as differential
access to care related to socioeconomic status that could
have led to lower rates of prior diagnoses of AF (ascertain-
ment bias). However, our sample included only insured
patients who belonged to an integrated healthcare delivery
system and who had equal access to hospitalization based on
their basic membership coverage, which decreases the like-
lihood of differential decision-making regarding hospital-
ization for HF. Both African American and Caucasian
subjects had similar mean duration of membership and
outpatient utilization rates before the index hospitalization,
suggesting equal opportunity to identify previously diag-
nosed AF. In addition, our observation that there were
similar rates of the presence of an S3 gallop, pulmonary
edema on chest X-ray, and similar distributions of ejection
fraction status between Caucasians and African Americans
suggests that confounding by severity of HF is less likely in
our sample. Another possible explanation for the lower
prevalence of AF in African Americans than in Caucasians
with HF may be intrinsic racial differences in atrial mem-
brane stability, atrial conduction pathways, or genetic poly-
morphisms leading to different susceptibility to the devel-
opment of AF. For example, polymorphisms have been
found to be associated with racial differences in risk for HF
(21) and response to treatment for HF (22). In addition,
recent data from the Cardiovascular Health Study have
demonstrated a smaller average left atrial size among elderly
African Americans than among Caucasians, which may help
to partially explain the lower prevalence of AF in African
Americans (23).
Our study had several strengths. This was a large,
contemporary cohort of patients hospitalized with HF that
included excellent representation of African Americans.
The cohort was assembled from a well-characterized man-
aged care population that is diverse and highly representa-
tive of the California state population (24). Prevalent AF
was determined by reviewing admission ECGs using stan-
dardized criteria in addition to the systematic review both of
medical records and of comprehensive automated clinical
databases for outpatient and inpatient diagnoses of AF. The
validity of our automated databases for the diagnosis of AF
is high (15). Information on traditional risk factors for AF,
targeted co-morbid conditions, and cardiac medications
were obtained from medical records in combination with
comprehensive automated outpatient, hospital discharge,
pharmacy, and laboratory databases (15,25).
Our study also had several limitations. Because of the
cross-sectional design of this study, we cannot accurately
determine whether AF developed before or after the initial
diagnosis of HF. Atrial fibrillation that was differentially
distributed between African American and Caucasian pa-
tients before the onset of HF could have led to an overes-
timate of racial differences in prevalence of AF. However,
because the prevalence of AF in the general population is
only slightly lower among African Americans than among
Caucasians (15), this is an unlikely explanation for the
434 Ruo et al. JACC Vol. 43, No. 3, 2004
Race and Atrial Fibrillation in HF February 4, 2004:429–35
magnitude of our and other studies’ findings. Another
limitation is that we could not accurately measure the
duration of HF or other co-morbid conditions. However,
the time frame for ascertainment of the various co-morbid
conditions as well as prior diagnosed outpatient or inpatient
HF (from medical records and clinical databases) was the
same for both groups. Our cohort was comprised of only
hospitalized patients with HF who likely represent a more
severe spectrum of HF, which may lead to a higher estimate
of the overall prevalence of AF but not the observed racial
differences. Finally, we analyzed data from an insured
population in northern California, so results may not be
completely generalizable to uninsured patients or other
geographic areas.
In sum, we found that African American race was
independently associated with a lower prevalence of AF
when compared with Caucasians in the setting of HF. The
reasons for a lower prevalence of AF among African
Americans with HF remain unclear, but further research
into the potential racial differences in clinical, physiological,
and genetic factors that affect the development of AF is
needed.
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